Arax Advisory Partners’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.04M | Buy |
31,841
+25,119
| +374% | +$4.72M | 0.04% | 430 |
|
|
2026
Q1 | $1.3M | Sell |
6,722
-866
| -11% | -$167K | 0.04% | 364 |
|
|
2025
Q4 | $1.4M | Sell |
7,588
-5,019
| -40% | -$880K | 0.04% | 307 |
|
|
2025
Q3 | $1.93M | Buy |
12,607
+10,022
| +388% | +$1.52M | 0.03% | 474 |
|
|
2025
Q2 | $424K | Sell |
2,585
-1,013
| -28% | -$142K | 0.02% | 435 |
|
|
2025
Q1 | $529K | Buy |
3,598
+1,493
| +71% | +$216K | 0.03% | 306 |
|
|
2024
Q4 | $276K | Buy |
2,105
+491
| +30% | +$68.7K | 0.02% | 423 |
|
|
2024
Q3 | $251K | Buy |
1,614
+23
| +1% | +$3.71K | 0.02% | 306 |
|
|
2024
Q2 | $248K | Buy |
1,591
+318
| +25% | +$47.9K | 0.02% | 294 |
|
|
2024
Q1 | $173K | Sell |
1,273
-28
| -2% | -$3.71K | 0.02% | 311 |
|
|
2023
Q4 | $175K | Buy |
1,301
+519
| +66% | +$67.5K | 0.02% | 300 |
|
|
2023
Q3 | $106K | Buy |
782
+28
| +4% | +$3.82K | 0.01% | 338 |
|
|
2023
Q2 | $108K | Buy |
754
+35
| +5% | +$5.15K | 0.01% | 336 |
|
|
2023
Q1 | $99.7K | Buy |
719
+63
| +10% | +$8.48K | 0.01% | 347 |
|
|
2022
Q4 | $88.9K | Sell |
656
-79
| -11% | -$9.91K | 0.01% | 352 |
|
|
2022
Q3 | $81K | Buy |
735
+707
| +2,525% | +$89.7K | 0.01% | 344 |
|
|
2022
Q2 | $4K | Buy |
28
+22
| +367% | +$2.89K | ﹤0.01% | 813 |
|
|
2022
Q1 | $1K | Sell |
6
-13
| -68% | -$1.56K | ﹤0.01% | 995 |
|
|
2021
Q4 | $2K | Buy |
19
+13
| +217% | +$1.53K | ﹤0.01% | 861 |
|
|
2021
Q3 | $1K | Sell |
6
-21
| -78% | -$2.44K | ﹤0.01% | 877 |
|
|
2021
Q2 | $3K | Buy |
+27
| New | +$2.96K | ﹤0.01% | 801 |
|
|
2020
Q4 | $3K | Hold |
27
| – | – | ﹤0.01% | 640 |
|
|
2020
Q3 | $3K | Buy |
+27
| New | +$3K | ﹤0.01% | 618 |
|
|
2018
Q3 | – | Sell |
-648
| Closed | -$45K | – | 624 |
|
|
2018
Q2 | $45K | Buy |
648
+4
| +0.6% | +$288 | 0.02% | 220 |
|
|
2018
Q1 | $45K | Buy |
644
+346
| +116% | +$24K | 0.02% | 211 |
|
|
2017
Q4 | $20K | Buy |
298
+6
| +2% | +$405 | 0.01% | 284 |
|
|
2017
Q3 | $19K | Sell |
292
-154
| -35% | -$9.73K | 0.01% | 274 |
|
|
2017
Q2 | $30K | Buy |
446
+415
| +1,339% | +$27.1K | 0.01% | 272 |
|
|
2017
Q1 | $1K | Buy |
+31
| New | +$1.8K | ﹤0.01% | 476 |
|
Other funds holding AZN
EP
IA
Arax Advisory Partners's AZN Position: Q2 2026 in Review
Arax Advisory Partners increased its AstraZeneca (AZN) stake by 374% in Q2 2026, buying an estimated $4.72M and bringing the position to 31,841 shares worth $6.04M. The position accounts for 0.04% of the portfolio, ranked #430.
Arax Advisory Partners first reported a position in AZN in Q1 2017 and has held it in 29 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Arax Advisory Partners held 31,841 shares of AstraZeneca worth $6.04M as of Q2 2026.
- Arax Advisory Partners bought 25,119 AstraZeneca shares in Q2 2026, an estimated $4.72M.
- AstraZeneca made up 0.04% of Arax Advisory Partners's portfolio in Q2 2026, its #430 holding.
- Arax Advisory Partners first reported a position in AstraZeneca in Q1 2017 and has held it in 29 quarters since.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.